Bicatero 50 mg contains Bicalutamide, a non-steroidal anti-androgen used primarily in the treatment of prostate cancer.
It is taken orally once daily, often as part of combination therapy. Bicalutamide helps block the effect of male hormones (androgens), which fuel the growth of prostate cancer cells.

Its oral, once-daily regimen makes it a convenient and effective choice for long-term management.

Mechanism of Action

Bicalutamide works by competitively inhibiting androgen receptors, thereby blocking the action of testosterone and dihydrotestosterone (DHT) in prostate tissue.

• Prostate cancer cells often rely on androgens to grow and survive.

• By preventing these hormones from binding to their receptors, bicalutamide halts tumour progression and may even cause cancer cells to shrink.

• Unlike some other hormone therapies, bicalutamide does not lower testosterone levels, but instead blocks its activity at the cellular level.

This mechanism allows it to be used in combination with luteinizing hormone-releasing hormone (LHRH) analogues or after surgical castration for enhanced androgen suppression.

Uses / Indications

Bicatero (Bicalutamide 50 mg) is primarily used for:

• Advanced prostate cancer, usually in combination with LHRH analogues (e.g., leuprolide or goserelin).

• Occasionally used in localized or locally advanced prostate cancer, as monotherapy in select cases or when patients are not suitable for other forms of treatment.

It is typically prescribed as part of a long-term hormone therapy regimen, and continued unless progression or intolerance occurs.

Adverse Effects

Because bicalutamide blocks male hormones throughout the body, it can cause side effects related to hormonal changes. Most are manageable but should be monitored.

Common side effects include:

• Hot flashes and sweating

• Breast tenderness or swelling (gynecomastia)

• Reduced libido, erectile dysfunction

• Fatigue and dizziness

• Gastrointestinal upset (nausea, constipation)